FDA touts new flexible approach to reviewing cell and gene therapies
Regulatory NewsJoanne S. Eglovitch
Advanced therapies/cell and gene therapyBiologics License Application (BLA)CBERChemistry, Manufacturing and Controls (CMC)ManufacturingProduct developmentRegulatory strategyUnited StatesUS Food and Drug Administration (FDA)